Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program
The Oncologist · 2023
DOI: 10.1093/oncolo/oyad137 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Oncologist, 2023. Verfasst von Fanny Le Du und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Centre Eugène Marquis, Rennes, France. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Trastuzumab, Chemotherapy, Adjuvant. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Roche, Pfizer, AstraZeneca.
Abstract (Originalsprache)
Background
Although adjuvant cancer treatments increase cure rates, they may induce clonal selection and tumor resistance. Information still lacks as whether (neo)adjuvant anti-HER2 treatments impact the patterns of recurrence and outcomes of HER2-positive (HER2+) metastatic breast cancer (MBC). We aimed to assess this in the large multicenter ESME real-world database. Patients and Methods We examined the characteristics and outcomes (overall survival (OS) and progression-free survival under first-line treatment (PFS1)) of HER2+ patients with MBC from the French ESME program with recurrent disease, as a function of the previous receipt of adjuvant trastuzumab. Multivariable analyses used Cox models adjusted for baseline demographic, prognostic factors, adjuvant treatment received, and disease-free interval.
Results
Two thousand one hundred and forty-three patients who entered the ESME cohort between 2008 and 2017 had a recurrent HER2+ MBC. Among them, 56% had received (neo)adjuvant trastuzumab and 2.5% another anti-HER2 in this setting. Patients pre-exposed to trastuzumab were younger, had a lower disease-free interval, more HR-negative disease and more metastatic sites. While the crude median OS appeared inferior in patients exposed to adjuvant trastuzumab, as compared to those who did not (37.2 (95%CI 34.4-40.3) versus 53.5 months (95% CI: 47.6-60.1)), this difference disappeared in the multivariable model (HR = 1.05, 95%CI 0.91-1.22). The same figures were observed for PFS1.
Conclusions
Among patients with relapsed HER2+ MBC, the receipt of adjuvant trastuzumab did not independently predict for worse outcomes when adjusted to other prognostic factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.
- Department of Biostatistics, Institut Curie, Saint-Cloud, France.
- Department of Medical Oncology, Centre Léon-Bérard, Lyon, France.
- Department of Medical Oncology, Hôpital Américain, Paris, France.
- Department of Cancer Medicine, Gustave Roussy, Villejuif, France.
- Department of Medical Oncology, Institut Curie/Saint Cloud, Paris, France.
ORCID-Profile: Fanny Le Du, Véronique Diéras
Förderung
- Roche
- Pfizer
- AstraZeneca
- Eisai and Daiichi Sankyo
- UNICANCER
Zitieren
APA
Le Du, F., Carton, M., Bachelot, T., Saghatchian, M., Pistilli, B., Brain, E., Loirat, D., Vanlemmens, L., Vermeulin, T., Emile, G., Gonçalves, A., Ung, M., Robert, M., Jaffre, A., Desmoulins, I., Jouannaud, C., Uwer, L., Marc Ferrero, J., Mouret-Reynier, M. A., …, & Diéras, V. (2023). Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program. The Oncologist. https://doi.org/10.1093/oncolo/oyad137
Vancouver
Le Du F, Carton M, Bachelot T, Saghatchian M, Pistilli B, Brain E, et al. Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program. The Oncologist. 2023. doi:10.1093/oncolo/oyad137
BibTeX
@article{LeDu2023,
author = {Le Du, Fanny and Carton, Matthieu and Bachelot, Thomas and Saghatchian, Mahasti and Pistilli, Barbara and Brain, Etienne and Loirat, Delphine and Vanlemmens, Laurence and Vermeulin, Thomas and Emile, George and Gonçalves, Anthony and Ung, Mony and Robert, Marie and Jaffre, Anne and Desmoulins, Isabelle and Jouannaud, Christelle and Uwer, Lionel and Marc Ferrero, Jean and Mouret-Reynier, Marie-Ange and Jacot, William and Chevrot, Michaël and Delaloge, Suzette and Diéras, Véronique},
title = {Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program},
journal = {The Oncologist},
year = {2023},
doi = {10.1093/oncolo/oyad137}
}
EUVIMED